Feed DOCS
DO

Doximity DOCS NYSE · Healthcare · United States

$29.62 -3.42% -$1.05

Summary

77 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 23% a year over the last 3 years.
  • Out of every 100 USD of revenue, 21 USD is left as net profit.
  • It holds more cash than debt: $218.6M against $9.15M.
  • It bought back its own shares for $431.7M in the last fiscal year, 8.2% of its market value.

What to watch

  • You pay 37.8 USD for 1 USD of yearly profit, a lot for its sector.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $29.62

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 37.8 21% lower
5-year average P/E 47.8
P/E today 37.8
Medical - Healthcare Information Services industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 37.8 USD for 1 USD of yearly profit. Over the last five years it was 47.8 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 26% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 5.5%. Earnings per share grew by 23% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Medical - Healthcare Information Services) 5.7 USD

Out of every 100 USD of revenue, 21 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $31.75 is 7.2% above today's price. 38% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2026

By product

By region

The company reports no revenue by region.

Subscription brings in 94% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy